Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F12 | P00748 | 5/20 | 1.00 |
| ▸ | PRSS1 | P07477 | 3/20 | 1.00 |
| ▸ | PRSS2 | P07478 | 1/20 | 1.00 |
| ▸ | PRSS3 | P35030 | 1/20 | 1.00 |
| ▸ | F2 | P00734 | 2/20 | 0.91 |
| ▸ | C1R | P00736 | 2/20 | 0.91 |
| ▸ | F10 | P00742 | 2/20 | 0.91 |
| ▸ | KLK1 | P06870 | 2/20 | 0.91 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.91 |
| ▸ | PTGIR | P43119 | 7/20 | 0.54 |
| ▸ | ADRA2B | P18089 | 5/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.53 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.52 |
| ▸ | MLNR | O43193 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | PLG | P00747 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.52 |
| ▸ | HPN | P05981 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sepimostat SCHEMBL9825206 | 0.99 | F12 (0.98) | F12PRSS1PRSS2PRSS3F2 | |
| Sepimostat SCHEMBL15536391 | 0.95 | PRSS1 (1.00) | F12PRSS1PRSS2PRSS3F2 | |
| Sepimostat SCHEMBL1228902 | 0.95 | PRSS1 (1.00) | F12PRSS1PRSS2PRSS3F2 | |
| Sepimostat SCHEMBL29406588 | 0.95 | PRSS1 (1.00) | F12PRSS1PRSS2PRSS3F2 | |
| SCHEMBL10035205 | 0.85 | PRSS1 (0.74) | F12PRSS1PRSS2PRSS3F2 | |
| Hydrochloric Acid SCHEMBL7563216 | 0.81 | PRSS1 (0.68) | F12PRSS1PRSS2PRSS3F2 | |
| Hydrochloric Acid SCHEMBL7584502 | 0.81 | PRSS1 (0.67) | F12PRSS1PRSS2PRSS3F2 | |
| Hydrochloric Acid SCHEMBL7591940 | 0.80 | PRSS1 (0.66) | F12PRSS1PRSS2PRSS3F2 | |
| SCHEMBL7598149 | 0.80 | PRSS1 (0.73) | F12PRSS1PRSS2PRSS3F2 | |
| SCHEMBL7563393 | 0.78 | PRSS1 (0.70) | F12PRSS1PRSS2PRSS3F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240189317-A1 | ANTIVIRAL COMPOSITIONS AND METHODS | ACADIA WOODS PARTNERS, LLC | 2024-06-13 | — | — | US | claimed |
| EP-4308103-A1 | ANTIVIRAL COMPOSITIONS AND METHODS | AI Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | claimed |
| US-20230414575-A1 | MK2 ACTIVATING COMPOUNDS FOR USE IN TREATING VASCULAR LEAK AND ENDOTHELIAL BARRIER DISORDERS | AKTTYVA THERAPEUTICS INC (US) | 2023-12-28 | — | — | US | claimed |
| EP-4244341-A2 | MK2 ACTIVATING COMPOUNDS FOR USE IN TREATING VASCULAR LEAK AND ENDOTHELIAL BARRIER DISORDERS | Akttyva Therapeutics, Inc. (US) | 2023-09-20 | — | — | EP | claimed |
| WO-2022265697-A1 | COMPOSITIONS FOR TREATING VIRAL INFECTIONS AND METHODS FOR SAME | Tiger Development, LLC (US) | 2022-12-22 | — | — | WO | claimed |
| US-20220370360-A1 | COMPOSITIONS FOR TREATING VIRAL INFECTIONS AND METHODS FOR SAME | ACCESS TO ADVANCED HEALTH INSTITUTE | 2022-11-24 | — | — | US | claimed |
| WO-2022197667-A1 | ANTIVIRAL COMPOSITIONS AND METHODS | YOUNG PETER R (US) | 2022-09-22 | — | — | WO | claimed |
| WO-2022133182-A1 | METHOD OF TREATING CORONAVIRUS INFECTION | CHAN ZUCKERBERG BIOHUB, INC. (US) | 2022-06-23 | — | — | WO | claimed |
| WO-2022104097-A2 | MK2 ACTIVATING COMPOUNDS FOR USE IN TREATING VASCULAR LEAK AND ENDOTHELIAL BARRIER DISORDERS | AKTTYVA THERAPEUTICS, INC. (US) | 2022-05-19 | — | — | WO | claimed |
| US-20210401751-A1 | COMPOSITIONS FOR TREATING VIRAL INFECTIONS AND METHODS FOR SAME | Tiger Development Inc. (US) | 2021-12-30 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| WO-2008142397-A1 | SERINE PROTEASE INHIBITORS FOR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | SERENTIS LIMITED (GB) | 2008-11-27 | — | — | WO | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-5932603-A | ORALLY ADMINISTERING 6-AMIDINO-2-NAPHTHYL4-((4,5-DIHYDRO-1H-IMIDAZOL-3-YL-)AMINO)BE NZOATE | TORII PHARMACEUTICAL CO., LTD. (JP) | 1999-08-03 | — | — | US | claimed |
| EP-0811377-A1 | THROMBOLYTIC AGENT | TORII PHARMACEUTICAL CO., LTD. (JP) | 1997-12-10 | — | — | EP | claimed |
| EP-0190356-B1 | NOVEL AMIDINE COMPOUNDS | TORII & CO., LTD. (JP) | 1991-03-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240189317-A1 | ANTIVIRAL COMPOSITIONS AND METHODS | PIKFYVE, APAF1, API5 | F12 2173/4885PRSS1 4/4885PRSS2 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.